Zhixun Finance APP News, Kemdi-B (02487) announcement, the group's potential Class 1 new drug CU-20401 (recombinant mutated collagenase) has completed the II phase clinical trial for the treatment of submental fat accumulation for all subjects who completed the study.

CU-20401 is a recombinant mutated collagenase that targets metabolic diseases related to obesity, overweight, or other localized fat accumulation. CU-20401 adopts an innovative mechanism of action as a collagenase, selectively targeting the extracellular matrix adhered to the adipose tissue. After local injection, CU-20401 degrades the collagen protein in the subcutaneous fat layer's extracellular matrix, leading to adipocyte apoptosis, which is expected to effectively reduce localized fat accumulation. CU-20401 catalyzes collagen degradation at a lower rate through technical improvements, possessing mild catalytic activity, thereby reducing the side effects of wild-type collagenases such as bruising and pain.

The phase II clinical trial of CU-20401 conducted in China for the treatment of submental fat accumulation is a multicenter, randomized, double-blind, and placebo-controlled trial to evaluate the effectiveness and safety of CU-20401.